Stock Screener App

Free -

4.15

1.34% 0.055

after-market

After Hours: 4.06 -0.09 -2.17%

Neurobo Pharmaceuticals Inc (NRBO)

Overview News Price History Financials Discussions Forecast Stock Split

Neurobo Pharmaceuticals Inc stock is traded at $4.15, with a volume of 14,553. It is up +1.34% in the last 24 hours and down -14.08% over the past month. NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.

See More

Previous Close:

$4.095

Open:

$4.06

24h Volume:

14,553

Market Cap:

$41.48M

Revenue:

-

Net Income/Loss:

$-12.47M

P/E Ratio:

-0.4675

EPS:

-8.877

Net Cash Flow:

$-10.85M

1W Performance:

-7.98%

1M Performance:

-14.08%

6M Performance:

+35.18%

1Y Performance:

+654.96%

1D Range:

$4.06

$4.26

52W Range:

$0.38

$6.7499

Neurobo Pharmaceuticals Inc Stock (NRBO) Company Profile

Name

Neurobo Pharmaceuticals Inc

Sector

Healthcare (1186)

Industry

Biotechnology (681)

Phone

(857) 702-9600

Address

545 CONCORD AVENUE, CAMBRIDGE, MA

Employee

8

Twitter

Next Earnings Date

2024-08-07

Latest SEC Filings

NRBO's Discussions on Twitter

Neurobo Pharmaceuticals Inc Stock (NRBO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-15-20	Initiated	H.C. Wainwright	Buy

Neurobo Pharmaceuticals Inc Stock (NRBO) Latest News

Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now - GlobeNewswire

GlobeNewswire Inc.

NeuroBo Pharmaceuticals (NASDAQ:NRBO) Shares Down 3.4% - Defense World

BIX 2024: From graveyard to breakthrough, MASH candidates on rise - BioWorld Online

BioWorld Online

NeuroBo Pharmaceuticals Releases Corporate Presentation Update - TipRanks

NeuroBo Pharmaceuticals Releases Corporate Presentation Update - TipRanks

NeuroBo Pharmaceuticals Releases Corporate Presentation Update - TipRanks

Neurobo Pharmaceuticals Inc Stock (NRBO) Financials Data

Revenue

Net Income

Cash Flow

EPS

$84.59

1.17%

$162.54

0.45%

$28.38

0.89%

$85.94

1.49%

$494.46

1.67%

$234.84

1.28%

Open in Yahoo | Open in Google | Open in Finviz | Open in MarketWatch | Open in EDGAR | Open in Reuters